Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications

Acute Lymphoblastic Leukemia (ALL) is the predominant hematological malignancy in pediatric populations, originating from B- or T-cell precursors within the bone marrow. The disease exhibits a high degree of heterogeneity, both at the molecular level and in terms of clinical presentation. A complex...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in pharmacology Vol. 14; p. 1322937
Main Authors:	Assis, Alan Jhones Barbosa, Santana, Brunna Letícia de Oliveira, Gualberto, Ana Cristina Moura, Pittella-Silva, Fabio
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 07-12-2023
Subjects:	acute lymphoblastic leukemia CRISPR/Cas9 current perspectives gene editing Pharmacology therapeutic strategies cancer treatment current perspectives therapeutic strategies cancer treatment CRISPR/Cas9 acute lymphoblastic leukemia gene editing
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Acute Lymphoblastic Leukemia (ALL) is the predominant hematological malignancy in pediatric populations, originating from B- or T-cell precursors within the bone marrow. The disease exhibits a high degree of heterogeneity, both at the molecular level and in terms of clinical presentation. A complex interplay between inherited and acquired genetic alterations contributes to disease pathogenesis, often resulting in the disruption of cellular functions integral to the leukemogenic process. The advent of CRISPR/Cas9 as a gene editing tool has revolutionized biological research, underscoring its potential to modify specific genomic loci implicated in cancer. Enhanced understanding of molecular alterations in ALL has facilitated significant advancements in therapeutic strategies. In this review, we scrutinize the application of CRISPR/Cas9 as a tool for identifying genetic targets to improve therapy, circumvent drug resistance, and facilitate CAR-T cell-based immunotherapy. Additionally, we discuss the challenges and future prospects of CRISPR/Cas9 applications in ALL.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Reviewed by: Sreekanth Vedagopuram, Brigham and Women’s Hospital and Harvard Medical School, United States Elyse Page, South Australian Health and Medical Research Institute (SAHMRI), Australia Edited by: Haigang Wu, Henan University, China
ISSN:	1663-9812 1663-9812
DOI:	10.3389/fphar.2023.1322937